Research programme: monoclonal antibody anticancer therapeutics - Novelogics Biotechnology

Drug Profile

Research programme: monoclonal antibody anticancer therapeutics - Novelogics Biotechnology

Latest Information Update: 02 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novelogics Biotechnology
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 02 Jun 2017 Research programme: monoclonal antibody anticancer therapeutics - Novelogics Biotechnologyies is available for licensing as of 02 Jun 2017. http://novelogics.com/
  • 17 May 2017 Novelogics Biotechnology and The Centre for Drug Research and Development agree to co-develop monoclonal antibody anti-cancer therapeutics for Cancer
  • 17 May 2017 Novelogics Biotechnology plans a phase I trial for Cancer in the first half of 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top